Matt’s broad experience in translational research, academic medicine, and business development has given him a unique perspective and skillset for advancing scientific innovation to patients with unmet medical needs. As VP of Business Development Matt is responsible for setting the partnering and business strategy for the development of Kernal’s clinical programs.
Most recently, Matt was Head of Hematology Strategy at AstraZeneca where he supported cross-functional efforts to expand the pipeline through internal R&D as well as external partnering. Prior to their acquisition by AstraZeneca, Matt was part of the Business Development team at Alexion Pharmaceuticals, functioning in successive capacities starting with Strategic Evaluation and working his way up to Global Head of Business Development. During his time at Alexion and AZ, Matt was involved in over a dozen business development transactions totaling ~$4.5B including M&A, licensing, discovery/development partnerships, option agreements, and divestitures.
Matt earned his Ph.D. in Molecular Immunology from the Roswell Park Cancer Institute and his M.D. from The Ohio State University. He subsequently completed residency in Internal Medicine at Yale-New Haven Hospital followed by a clinical fellowship in Hematology at the Yale Cancer Center. Before transitioning to industry, Matt was an Assistant Professor of Medicine at Yale in the Section of Hematology.